Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Jonas Hallén"'
Autor:
Kristina Malene Ødegaard, Sandre Svatun Lirhus, Hans Olav Melberg, Jonas Hallén, Sigrun Halvorsen
Publikováno v:
ESC Heart Failure, Vol 10, Iss 1, Pp 405-415 (2023)
Abstract Aims We aimed to study initiation, adherence, and long‐term persistence to beta‐blockers (BB), renin–angiotensin system inhibitors (RASi), and mineralocorticoid receptor antagonists (MRA) in a nationwide cohort of patients with heart f
Externí odkaz:
https://doaj.org/article/aa6c93a4e4dc4be9b4f39df908642e86
Autor:
Kristina Malene Ødegaard, Sandre Svatun Lirhus, Hans Olav Melberg, Jonas Hallén, Sigrun Halvorsen
Publikováno v:
BMC Cardiovascular Disorders, Vol 22, Iss 1, Pp 1-12 (2022)
Abstract Background The incidence of heart failure (HF) has declined in Europe during the past two decades. However, incidence estimates from registry-based studies may vary, partly because they depend on retrospective searches to exclude previous ev
Externí odkaz:
https://doaj.org/article/c6fd914107ff48a98671964b4b81a02c
Incidence, prevalence, and mortality of heart failure: a nationwide registry study from 2013 to 2016
Autor:
Kristina Malene Ødegaard, Jonas Hallén, Sandre Svatun Lirhus, Hans Olav Melberg, Sigrun Halvorsen
Publikováno v:
ESC Heart Failure, Vol 7, Iss 4, Pp 1917-1926 (2020)
Abstract Aims Large‐scaled population studies of incidence and prevalence of heart failure (HF) are needed for the development of healthcare policies and priorities. The aim of this study was to estimate the incidence, prevalence, and all‐cause m
Externí odkaz:
https://doaj.org/article/b761d635fabc4c159912252d95b2fd2d
Autor:
Christopher P Denton, Shiwen Xu, Rory H Maclean, Kristina E Clark, Signe Borchert, Rizwan Hussain, Jorg Klingelhöfer, Jonas Hallén, Voon H Ong
Publikováno v:
Rheumatology. 62
Background/Aims Preclinical studies suggest that the S100A4, a Damage Associated Molecular Pattern (DAMP) protein upregulated upon stress or injury, may be a target for antifibrotic therapy. We have studied expression and function of S100A4 in system
Autor:
Kristina Malene Ødegaard, Sandre Svatun Lirhus, Hans Olav Melberg, Jonas Hallén, Sigrun Halvorsen
Aims - We aimed to study initiation, adherence, and long-term persistence to beta-blockers (BB), renin–angiotensin system inhibitors (RASi), and mineralocorticoid receptor antagonists (MRA) in a nationwide cohort of patients with heart failure (HF)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4387379a5e3e212ec77d6f2b5dbc77a
https://hdl.handle.net/10037/27619
https://hdl.handle.net/10037/27619
Incidence, prevalence, and mortality of heart failure: a nationwide registry study from 2013 to 2016
Autor:
Jonas Hallén, Kristina Malene Ødegaard, Hans Olav Melberg, Sigrun Halvorsen, Sandre Svatun Lirhus
Publikováno v:
ESC Heart Failure, Vol 7, Iss 4, Pp 1917-1926 (2020)
ESC Heart Failure
ESC Heart Failure
Aims Large‐scaled population studies of incidence and prevalence of heart failure (HF) are needed for the development of healthcare policies and priorities. The aim of this study was to estimate the incidence, prevalence, and all‐cause mortality
Autor:
Olav W. Nielsen, Georg Ertl, Jose Lopez-Sendon, Aldo P. Maggioni, Jonas Hallén, Maryam Aalamian-Mattheis, Yaqin Wang
Publikováno v:
European Journal of Heart Failure. 21:322-333
Aim Serelaxin is a recombinant human relaxin-2 hormone, which confers receptor-mediated vasodilatation in a tissue-specific fashion. The RELAX-AHF-EU study assessed the effect of serelaxin when added to standard-of-care (SoC) therapy on worsening hea
Autor:
Jose Lopez Sendon, Georg Ertl, Klaus K. Witte, Esteban López-de-Sá, Chien-Wei Chen, Jonas Hallén, Thomas Holbro, Fabio Turazza, Martin R. Cowie, Ulf Dahlström, Aldo P. Maggioni, Claudio Gimpelewicz, Erland Erdmann, Olav W. Nielsen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4538c99b881c8276f1dd639b9e5a8cdd
Autor:
David G. Orloff, Harold E. Bays, Svein Olaf Hustvedt, John J.P. Kastelein, David A. Fraser, Rong Zhou, Runar Vige, Jonas Hallén
Publikováno v:
Cardiology, 135(1), 3-12. S. Karger AG
Objectives: To evaluate the efficacy and safety of icosabutate, an oral, once-daily, first-in-class medication, in reducing non-high-density lipoprotein cholesterol (non-HDL-C) in patients with persistent hypertriglyceridemia despite statin therapy.
Publikováno v:
Clinical Laboratory. 64